e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review

e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

e-Therapeutics Plc (e-Therapeutics) is a drug discovery and development company with a focus on discovering novel therapeutic approaches and mechanisms for the treatment of various diseases such as cancer, diabetes, and neurodegenerative disease. It carries out its work by integrating proprietary databases and computational tools that use network analysis, machine learning, Al, data mining, and optimization. The company harnesses its two proprietary, productive, and unique technology platforms, Network-Driven Drug Discovery (NDD) and Genome Associated Network Interactions (GAINs), for the target of validation and novel discovery. e-Therapeutics has a research partnership with Novo Nordisk for developing therapeutics for type 2 diabetes. e-Therapeutics is headquartered in London, the UK.

e-Therapeutics Plc Key Recent Developments

May 11,2023: e-Therapeutics plc Notice of AGM and Posting of Annual Report
Feb 07,2023: e-therapeutics : Filing of four new patent applications on novel target innovation and new siRNA chemistries
Sep 30,2022: e-therapeutics : Interim results for the six months to 31 July 2022
Jul 20,2022: e-therapeutics announce Result of Annual General Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
e-Therapeutics Plc - Key Facts
e-Therapeutics Plc - Key Employees
e-Therapeutics Plc - Key Employee Biographies
e-Therapeutics Plc - Major Products and Services
e-Therapeutics Plc - History
e-Therapeutics Plc - Company Statement
e-Therapeutics Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
e-Therapeutics Plc - Business Description
R&D Overview
e-Therapeutics Plc - Corporate Strategy
e-Therapeutics Plc - SWOT Analysis
SWOT Analysis - Overview
e-Therapeutics Plc - Strengths
e-Therapeutics Plc - Weaknesses
e-Therapeutics Plc - Opportunities
e-Therapeutics Plc - Threats
e-Therapeutics Plc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
e-Therapeutics Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 11, 2023: e-Therapeutics plc Notice of AGM and Posting of Annual Report
Feb 07, 2023: e-therapeutics : Filing of four new patent applications on novel target innovation and new siRNA chemistries
Sep 30, 2022: e-therapeutics : Interim results for the six months to 31 July 2022
Jul 20, 2022: e-therapeutics announce Result of Annual General Meeting
May 17, 2022: e-Therapeutics Announces Notice of Annual General Meeting
May 04, 2022: e-therapeutics announces final results for the year ended 31 January 2022.
Apr 12, 2022: e-therapeutics announces key milestone achieved and significant progress on Galapagos collaboration
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
e-Therapeutics Plc, Key Facts
e-Therapeutics Plc, Key Employees
e-Therapeutics Plc, Key Employee Biographies
e-Therapeutics Plc, Major Products and Services
e-Therapeutics Plc, History
e-Therapeutics Plc, Other Locations
e-Therapeutics Plc, Subsidiaries
e-Therapeutics Plc, Key Competitors
e-Therapeutics Plc, Ratios based on current share price
e-Therapeutics Plc, Annual Ratios
e-Therapeutics Plc, Annual Ratios (Cont...1)
e-Therapeutics Plc, Annual Ratios (Cont...2)
e-Therapeutics Plc, Interim Ratios
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
e-Therapeutics Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
e-Therapeutics Plc, Performance Chart (2019 - 2023)
e-Therapeutics Plc, Ratio Charts
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
e-Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings